

1st Peptide Therapeutics Symposium

Programme – Day 1

Day One – February, 4th 2016

07.30-08.25	Registration & Coffee
08.25-08.35	<u>Welcome words</u> Olivier Duclos , LGCR & Philippe Subiron , Chilly site Director
08.35-09.00	<u>Opening remarks</u> Marc Bonnefoi , VP R&D Hub France Carlos Garcia-Echeverria , SMDD, Deputy LGCR
Session 1	Emerging and Validated Targets : Think Peptide!
	Session Chair s: Everard Pap (Sanofi ,LGCR)/tbd
09.00-09.40	<u>Keynote Address</u> Fernando Albericio , University of KwaZulu-Natal, Durban, South-Africa <i>Cyclic Peptides from the Nature to the Laboratory</i>
09.40-10.10	Michel De Waard , INSERM & Smartox, Grenoble, France <i>Animal Venoms and Therapeutic Peptides</i>
10.10-10.40	Networking coffee break
10.40-11.10	Christian Heinis , EPFL, Lausanne, Switzerland <i>Phage Selection of Bicyclic Peptides for Application as Therapeutics</i>
11.10-11.40	Kathlynn C. Brown , SRI International, Harrisonburg,USA <i>The Hunt for Cancer Targeting Peptides: New Ligands for Precision Therapy of Lung Cancer</i>

Day One – February, 4th 2016

Session 2	Optimizing Peptide for Tomorrow's Therapeutics : What's New?
	Session Chairs : Ram Dharanipragada (LGCR)/Evelyne Fontaine (ID)
11.40-12.20	<u>Keynote Address</u> Knud J. Jensen , University of Copenhagen, Denmark <i>Controlling the Properties of Peptides and Proteins at Nano-scale</i>
12.20-12.50	David Fairlie , University of Queensland, Brisbane, Australia <i>Cyclic Peptides and Oral Bioavailability: Challenging Convention</i>
12.50-13.50	Networking lunch
13.50-14.20	Horst Kessler , Technische Universität München, Germany <i>Peptides and Peptidomimetics in Medicine: Overcoming Problems of Activity, Selectivity, Metabolic Stability and Bioavailability for Integrin Ligands?</i>
14.20-14.50	Jean Martinez , Université de Montpellier 1, France <i>tbd</i>

1st Peptide Therapeutics Symposium

Programme – Day 2

Day One – February, 4th 2016

Session 3	Formulation and Delivery : How to Make Peptide Better!
	Session Chair: Rachel Vogel (Sanofi, LGCR)/tbd
14.50-15.30	<p><u>Keynote Address</u> Claus-Michael Lehr, University of Saarland, Saarbrücken, Germany <i>Non- Invasive Drug Delivery Across Epithelial Barriers (gut, skin, lung) - Nanotechnology Approaches and Advanced in vitro-Models</i></p>
15.30-16.00	<p>Robert Miller, Sanofi-Genzyme, Waltham, USA <i>Sub-cutaneous Depot for Sustained Delivery : Hydrogel vs Microparticules</i></p>
16.00-16.30	Afternoon refreshments + Networking
16.30-17.00	<p>David Brayden, University College Dublin, Ireland <i>Innovative Formulation Approaches to Achieve Oral Peptide Delivery</i></p>
17.00-17.30	<p>Joke Bouwstra, Leiden Academic Center , Netherlands <i>Microneedles Technologies for Transdermal Delivery of Peptides and Proteins</i></p>
17.30-18.00	<p>Zhen Gu, University of North Carolina at Chapel Hill, USA <i>Smart Insulin Delivery: Opportunities and Challenges</i></p>
18.00-18.05	Day 1 closing words
18.05-19.05	Cocktail & 1:1 Meetings with Speakers
19.05-22.00	Dinner by invitation only

Day Two – February, 5th 2016

Session 4	From Bench to Bedside : The Future is Now!
	Session Chairs : Matthias Urmann (Sanofi, Diabetes Division) /tbd
08.30-09.00	Welcome coffee
09.00-09.40	<p><u>Keynote Address</u> Sylviane Muller, CNRS, IBMC, Strasbourg, France <i>Peptide-Based Strategies to Treat Inflammatory and Autoimmune Diseases: a Translational Experience from Bench to Clinical Studies</i></p>
09.40-10.10	<p>Rudolf Goeller, Sanofi CBD, Frankfurt, Germany <i>Lixisenatide from Proof of Concept to Market</i></p>
10.10-11.10	Networking coffee break & 1:1 Meetings with Speakers
11.10-11.40	<p>Daniel Kramer, Sanofi DSAR, Frankfurt, Germany <i>Immunogenicity Risk Assessment</i></p>
11.40-12.10	<p><u>Concluding address</u> Philip Just Larsen, Sanofi Diabetes Division R&D, Frankfurt, Germany <i>tbd</i></p>
12,10-12,15	Farewell words
12.15-13,15	Lunch & Networking
End of the Peptide Therapeutics Symposium	